Notice of Intent to Publish a Funding Opportunity Announcement for Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional)
Notice Number:

Key Dates

Release Date:
January 18, 2022
Estimated Publication Date of Funding Opportunity Announcement:
March 31, 2022
First Estimated Application Due Date:
July 29, 2022
Earliest Estimated Award Date:
April 28, 2023
Earliest Estimated Start Date:
April 28, 2023
Related Announcements


Issued by

National Center for Advancing Translational Sciences (NCATS)

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

National Institute of Dental and Craniofacial Research (NIDCR)

National Institute of General Medical Sciences (NIGMS)

National Institute on Minority Health and Health Disparities (NIMHD)

All applications to this funding opportunity announcement should fall within the mission of the Institutes/Centers. The following NIH Offices may co-fund applications assigned to those Institutes/Centers.

Office of Behavioral and Social Sciences Research (OBSSR)

Office of Research on Women's Health (ORWH)


The National Center for Advancing Translational Science (NCATS), with other participating NIH Institutes, Centers, and Offices (ICOs), intends to continue promoting a Clinical and Translational Science Award (CTSA) Program Initiative by publishing a Funding Opportunity Announcement (FOA) to solicit applications for research on translational science. The CTSA Program Collaborative and Innovative Acceleration Award (CCIA) supports synergistic activities that accelerate the translational research process through collaboration and innovation. This new CCIA FOA will support phased awards to develop, demonstrate and disseminate innovative solutions to transform the field of translational science by addressing the inefficiencies that are common across diseases and bringing more interventions to all people more quickly through collaborative science among the CTSA Program hubs, NIH ICOs, and/or external stakeholders.

This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. NIDCR seeks to support an application with a PI/PIs affiliated with one or more US dental schools.

The FOA is estimated to be published in Spring 2022 with an estimated application due date in Summer 2022.

This FOA will utilize the UG3/UH3 Exploratory/Developmental Phased Award Cooperative Agreement activity code. Details of the planned FOA are provided below.

Research Initiative Details


Translating biomedical discoveries and behavioral observations into clinical applications and public health practice is essential to improving human health. NCATS is transforming translational science by relying on the power of data, new technologies, community and stakeholder engagement and collaborative science to develop, demonstrate and disseminate innovative solutions that reduce, remove or bypass costly and time-consuming bottlenecks in translational research. NCATS and CTSA Program Consortium’s efforts are intended to complement and empower translational research activities supported by NIH ICOs and/or external stakeholders, including but are not limited to, other US federal government agencies, state and local health departments, tribal nations, US government support organizations, industry, contract research organizations, research institutes, non-profit organizations, foundations, professional associations, patient organizations, and small business and entrepreneurs, academic institutions, private sector, and community groups. By emphasizing innovation and collaborative science, NCATS serves as a catalyst to enable all entities in the translational research enterprise to work more efficiently and effectively to bring more interventions to all people more quickly. For additional information, please see the NCATS strategic principles and the CTSA Program goals.

Since 2015, NCATS has established the CCIA initiative to stimulate complementary collaborations that build on the strength of the CTSA consortium while generating innovative solutions to benefit translational science that no single CTSA hub can accomplish alone. The expired U01 Research Project Cooperative Agreements (PAR-19-099) and R21 Exploratory/Developmental Research Grant (PAR-19-100) will not be reissued and will be replaced by the new FOA UG3/UH3 Exploratory/Developmental Phased Award Cooperative Agreement.

Specific Objectives

Each research stage across the translational science spectrum, from target validation through intervention development to public health benefit assessment, is currently fraught with inefficiency and in need of bold, new, innovative solutions. As such, there is a corresponding need for bold, new, innovative experimental approaches to identifying such solutions.

NCATS strongly encourages investigators to form new collaborations or expand existing collaborations to accelerate innovative and collaborative translational research projects carried out within and beyond the CTSA Program Consortium. The CCIA projects should build on the strengths and resources of each individual CTSA, translational research activities supported by NIH ICOs, and/or external stakeholders to accomplish a generally applicable translational science advance through collaborative science. Such projects should develop or adapt an innovative technology, method, or strategy that helps to overcome general roadblocks in science and/or operations, as well as translational science training, that limit the efficiency and effectiveness of translation. Such projects should demonstrate in one or more use cases whether the technology, method, or strategy is effective in accelerating research translation, utilizing clear and meaningful metrics and outcomes, when implemented across multiple CTSAs, NIH ICO translational research programs, and/or external stakeholders. The success of the CCIA projects should be specific and measurable. If successful, such projects should have a plan to disseminate the effective technology, method, or strategy across and beyond the CTSA Program in a sustainable manner.

Funding Information
Estimated Total Funding


Expected Number of Awards


Estimated Award Ceiling

Up to $650,000.00 direct cost annual budget for both UG3/UH3 Phases

Primary Assistance Listing Number(s)


Anticipated Eligible Organizations

Applications are not being solicited at this time.


Please direct all inquiries to:

Soju Chang, M.D., M.P.H.

National Center for Advancing Translational Sciences (NCATS)